# Research Input Analysis Report

- **Source Files Analyzed:** 2
- **Source Word Count:** 205 words
- **Canonical Fields Extracted:** 11 / 18

## Recommended Poster Direction

- **Template:** `meta-analysis`
- **Layout Recipe:** `systematic_review_prisma`
- **Color Palette:** `burgundy_offwhite`
- **Typography Pairing:** `editorial_modern`
- **Rationale:** Detected quantitative synthesis / heterogeneity / pooled effect terminology.

## Missing Information Audit (Zero-Fabrication Check)

### Essential Fields Not Found in Source (Clarification Recommended)
- [ ] 8. Study population
- [ ] 11. Primary outcome

### Optional / Secondary Fields Not Present (Omit Cleanly Unless Supplied)
- 4. Research gap
- 10. Statistical methods
- 12. Secondary outcomes
- 17. References
- 18. Funding and acknowledgements

## Extracted 18-Field Summary

### 1. Research title
GLP-1 Receptor Agonists and Major Adverse Kidney Events in Type 2 Diabetes: A Synthetic Meta-Analysis of 8 Randomized Trials

### 2. Authors and affiliations
Sophia Chen, MD, PhD; David Okafor, PhD; Claire Moreau, MD | Affiliations: Renal Trials Synthesis Group, Synthetic Institute of Medical Research (SYNTHETIC DATA)

### 3. Background
Individual cardiovascular outcome trials suggest renoprotective effects of GLP-1 receptor agonists (GLP-1RA), but precision for sustained kidney failure and renal death across CKD stages warranted pooled synthesis.

### 4. Research gap
_Not present in supplied source material._

### 5. Objectives
Quantify pooled random-effects hazard ratios for Major Adverse Kidney Events (MAKE: >=50% eGFR decline, kidney failure, or renal death) across placebo-controlled RCTs.

### 6. Study design
Meta-Analysis

### 7. Methods
Restricted maximum likelihood (REML) random-effects meta-analysis with Hartung-Knapp adjustment across 8 RCTs (N = 52,640 participants). Heterogeneity was quantified via I² = 28.4%, τ² = 0.006, Cochran Q = 9.78 (p_het = 0.20), and 95% prediction interval.

### 8. Study population
_Not present in supplied source material._

### 9. Sample size
N = 52,640

### 10. Statistical methods
_Not present in supplied source material._

### 11. Primary outcome
_Not present in supplied source material._

### 12. Secondary outcomes
_Not present in supplied source material._

### 13. Important findings
Pooled random-effects HR was 0.76 (95% CI 0.69–0.84, p = 0.0001; 95% prediction interval 0.61–0.95). Egger regression showed no small-study asymmetry (p = 0.41).

### 14. Tables and figures
```json
{
  "manuscript_tables": [],
  "datasets": [
    {
      "file": "/home/user/research-poster-maker/tests/case_03_meta_analysis/inputs/meta_trials.csv",
      "format": "csv",
      "row_count": 8,
      "columns": [
        "study",
        "n",
        "effect",
        "ci_low",
        "ci_high",
        "weight",
        "se",
        "subgroup"
      ],
      "preview_rows": [
        [
          "RENAL-FLOW Synthetic 2021",
          "3533",
          "0.76",
          "0.66",
          "0.88",
          "21.4",
          "0.073",
          "Dedicated Kidney Outcome Trials"
        ],
        [
          "NEPHRO-GLP Synthetic 2023",
          "4120",
          "0.72",
          "0.61",
          "0.85",
          "17.8",
          "0.084",
          "Dedicated Kidney Outcome Trials"
        ],
        [
          "CARDIO-REN Synthetic 2020",
          "9901",
          "0.78",
          "0.65",
          "0.93",
          "14.9",
          "0.091",
          "Cardiovascular Outcome Trials (CKD Strata)"
        ],
        [
          "VASC-PROTECT Synthetic 2021",
          "8416",
          "0.84",
          "0.69",
          "1.02",
          "12.6",
          "0.1",
       
```

### 15. Limitations
Trial-level aggregate data precluded continuous eGFR slope modeling at individual patient level; background SGLT2i use ranged from 0% to 18.2%.

### 16. Conclusion
GLP-1 receptor agonists reduce major adverse kidney events by 24% with low between-trial heterogeneity across dedicated renal and cardiovascular trials.

### 17. References
_Not present in supplied source material._

### 18. Funding and acknowledgements
_Not present in supplied source material._
